Advertisment
Sobi to unveil new data at the annual European Association for Haemophilia and Allied Disorders (EAHAD 2025)
Sobi will unveil new data at the annual European Association for Haemophilia and Allied Disorders (EAHAD 2025) congress in Milan from the 4th – 7th February, 2025. Outcomes and analyses investigating the effectiveness of Altuvoct and Elocta in adults, adolescents, and children with haemophilia A will be presented, further showcasing Sobi’s commitment to advancing standards of care in haemophilia.
“People with haemophilia can experience bleeding episodes that can cause pain, irreversible joint damage, and life-threatening haemorrhages,” said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs, and Chief Medical Officer at Sobi. “At EAHAD 2025, Sobi’s poster and oral presentations will demonstrate the important progress that has been made in the treatment of haemophilia A, as we continue to move the treatment paradigm towards normal haemostasis. We look forward to sharing our findings in Milan.”